Track the offering's close by August 14, 2026 — actual proceeds will determine cash runway into Q1 2027 at best. The absence of a minimum means investors should expect high volatility and potential for a failed offering. Monitor for any pricing discount to the $2.19 assumed price, which would further dilute and trigger additional warrant adjustments.
Executive Summary
Moleculin Biotech filed Amendment No. 1 to its S-1 for a best-efforts offering of up to 4.57M shares (plus pre-funded warrants) and 13.7M Series I warrants at an assumed $2.19/unit, with no minimum proceeds. The company, a pre-revenue clinical-stage biotech developing Annamycin for R/R AML, expects ~$9.1M net proceeds at max to fund development. This is the 24th equity offering in 24 months for a $7M market cap, making dilution extreme and the offering highly uncertain given the absence of a minimum.
Key Facts
- Best-efforts offering of up to 4,566,210 shares (or pre-funded warrants) plus 13,698,630 Series I warrants (3 per share) at assumed $2.19/unit, expiring 5 years after exercise start.
- No minimum offering amount — proceeds could be far below the $9.1M maximum estimate, and investors receive no refund if insufficient funds raised.
- Company has no revenue and had net tangible book value of $4.0M ($0.76/share) as of March 31, 2026; new investors face immediate dilution of $0.87/share at assumed price.
- Offering triggers anti-dilution adjustments on existing Series G and H warrants (covering 8.98M shares), reducing their exercise prices to the new issuance price, subject to floor prices of $1.326 and $0.962.
- Insiders (officers/directors) have indicated potential participation but commitments are non-binding; $9.1M estimated net proceeds intended for Annamycin clinical development and working capital.
Financial Impact
Up to $9.1M net proceeds at max, but could be drastically lower with no minimum. Existing 12.4M warrants at $2.52 weighted average exercise price plus new Series I warrants create massive overhang.
Risk Factors
- Best-efforts offering with no minimum may fail to raise sufficient capital, accelerating need for distressed financing.
- Extreme dilution: outstanding shares will nearly double from 5.3M to ~9.9M (excluding warrants), with additional 13.7M Series I warrants and anti-dilution adjustments on existing warrants.
- Company requires significant additional financing beyond this offering to complete the MIRACLE trial; no committed funding sources exist.
- Nasdaq delisting risk remains if stockholders' equity or bid price falls below continued listing standards.
- Series I warrants require stockholder approval to become exercisable; if approval is not obtained, warrants have no value, potentially deterring investor demand.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001437749-26-025100 |
| Document: 0001437749-26-025100-index-headers.html | 0001437749-26-025100 |
| Document: 0001437749-26-025100-index.html | 0001437749-26-025100 |
| Document: 0001437749-26-025100.txt | 0001437749-26-025100 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | 8-K | $6.19 | awaiting T+20 | — | $7.95 (+28.43%) |
Oct 16, 2026 11d ago | 8-K | $0.2804 | awaiting T+20 | — | $7.95 (+2735.24%) |
Oct 9, 2026 17d ago | 8-K | $0.4139 | awaiting T+20 | — | $7.95 (+1820.75%) |
Oct 5, 2026 22d ago | 8-K | $0.4766 | awaiting T+20 | — | $7.95 (+1568.07%) |
Sep 29, 2026 28d ago | 8-K | $0.5264 | awaiting T+20 | — | $7.95 (+1410.26%) |
Sep 29, 2026 28d ago | Press Release | $0.5264 | awaiting T+20 | — | $7.95 (+1410.26%) |
Sep 28, 2026 29d ago | 8-K | $0.5690 $7.09 | ▲ +1145.17% | ▲ +1145.20% | $7.95 (+1297.19%) |
Sep 25, 2026 4w ago | 8-K | $0.6016 $6.50 | ▲ +980.45% | ▲ +981.93% | $7.95 (+1221.48%) |
Sep 23, 2026 4w ago | 8-K | $0.5279 $6.31 | ▲ +1095.30% | ▲ +1094.61% | $7.95 (+1405.97%) |
Sep 18, 2026 5w ago | 8-K | $0.5202 | awaiting T+20 | — | $7.95 (−1428.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers